However, clinical studies clearly demonstrated that GIP insensitivity in type 2 diabetes mellitus is surmountable (Højberg et al., 2009), suggesting potential for additive antidiabetic benefits of GIP alongside GLP‐1 in humans. The gene discussed is GCG; the disease is type 2 diabetes mellitus.